DGIdb - DACTOLISIB Drug Record

DACTOLISIB chembl:CHEMBL1879463 Antineoplastic

Alternate Names:

NVP-BEZ235
DACTOLISIB
BEZ-235
NVP-BEZ235-NX
BEZ235

Drug Info:

Notes	catalytic, dual PI3K/mTOR inhibitor
Drug Class	Kinase Inhibitors
Pharmaceutical Developer	Novartis
Source Reported Drug Name(s)	BEZ235
Drug Class	PI3K/mTOR dual Inhibitor

(8 More Sources)

Publications:

Morales GA et al., 2013, Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors., J Med Chem
Coffee et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin. Cancer Res.
Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol
Wang et al., 2014, Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation., Mol. Cancer Ther.
García-García et al., 2015, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clin. Cancer Res.
Lui et al., 2013, Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers., Cancer Discov
Engelman et al., 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers., Nat. Med.
Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
Depreeuw et al., 2015, Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies., Gynecol. Oncol.
Swick et al., 2017, Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC., Mol. Cancer Ther.
Oishi et al., 2014, The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma., Oncol. Rep.
Roper et al., 2011, The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer., PLoS ONE
Bonelli et al., 2015, Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations., Mol. Cancer Ther.
Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
Mueller et al., 2012, Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines., Cancer Chemother. Pharmacol.
Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
Kim et al., 2013, Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer., Int. J. Cancer
Dogruluk et al., 2015, Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations., Cancer Res.
Shoji et al., 2012, Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas., PLoS ONE
Eichhorn PJ et al., 2008, Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235., Cancer Res
Migliardi et al., 2012, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas., Clin. Cancer Res.
Soares et al., 2015, Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2., Mol. Cancer Ther.
Raja et al., 2015, Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer., Mol. Cancer Ther.
Choong et al., 2013, Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors., J. Cell. Mol. Med.
Jin et al., 2011, Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer., Clin. Cancer Res.

DACTOLISIB CRTC1

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
DACTOLISIB CRTC2

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
DACTOLISIB MPL

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
24251790

Sources:
JAX-CKB
DACTOLISIB PIK3CA

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
23619167 19029981 26270481 26232337 28446642 24927217 26137449 21966435 26013318 26272063 23629727 27974663 22543857 24939055 23475782 26627007 22662154 19010894

Sources:
ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial
DACTOLISIB PIK3R4

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
DACTOLISIB PIK3R6

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial
DACTOLISIB PIK3R1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB APC

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Binimetinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
26206338

Sources:
JAX-CKB
DACTOLISIB PIK3R5

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB PIK3R3

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB KRAS

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22392911 19029981 23629727 25673820 24939055 23475782 22662154 26272063 26232337 26206338

Sources:
JAX-CKB CIViC
DACTOLISIB PIK3R2

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + BEZ235

Indication/Tumor Type endometrial cancer

Response Type sensitive

PMIDs:
28446642 27974663 26206338 22662154 26232337

Sources:
ClearityFoundationBiomarkers JAX-CKB
DACTOLISIB PIK3C2A

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
DACTOLISIB PIK3C3

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
DACTOLISIB NEK2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB PIK3C2B

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
DACTOLISIB PIK3C2G

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
DACTOLISIB PIK3CD

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB HRAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
21831957

Sources:
JAX-CKB
DACTOLISIB PIK3CB

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
DACTOLISIB MTOR

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
23410005

Sources:
DTC MyCancerGenome ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial TTD
DACTOLISIB ACVR1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB LIMK1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB PIK3CG

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial TTD
DACTOLISIB CDK7

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB LTK

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB NRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22392911

Sources:
CIViC
DACTOLISIB LRRK2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB BRAF

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Vemurafenib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
23549875 26137449

Sources:
JAX-CKB CIViC
DACTOLISIB MAP4K2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB JAK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
24251790

Sources:
JAX-CKB
DACTOLISIB FGFR3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib + BEZ235

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

PMIDs:
26270481

Sources:
JAX-CKB
DACTOLISIB MAP4K5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB CHEK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24939055

Sources:
DTC JAX-CKB
DACTOLISIB CSF1R

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB CLK4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB ALK

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB EGFR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + BEZ235

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
24939055 23629727

Sources:
JAX-CKB
DACTOLISIB AURKB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DACTOLISIB TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Response Type decreased response

Response Type sensitive

PMIDs:
26272063

Sources:
JAX-CKB
DACTOLISIB AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24356815

Sources:
CIViC
DACTOLISIB NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

CancerCommons: BEZ235
- Version: 25-July-2013
Alternate Names:

Dactolisib PubChem Drug Name

11977753 PubChem Drug ID

BEZ235 Drug Trade Name

Drug Info:

Drug Class PI3K/mTOR dual Inhibitor

Source Reported Drug Name(s) BEZ235

Pharmaceutical Developer Novartis

Publications:
MyCancerGenome: BEZ235
- Version: 20-Jun-2017
Alternate Names:

BEZ235 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Notes catalytic, dual PI3K/mTOR inhibitor

Publications:
DTC: DACTOLISIB
- Version: 02-September-2020
Alternate Names:

CHEMBL1879463 ChEMBL Drug ID

Drug Info:

Publications:

Morales GA et al., 2013, Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors., J Med Chem

JAX-CKB: BEZ235

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Jin et al., 2011, Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer., Clin. Cancer Res.

Choong et al., 2013, Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors., J. Cell. Mol. Med.

Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.

CIViC: DACTOLISIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Coffee et al., 2013, Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer., Clin. Cancer Res.

Wang et al., 2014, Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation., Mol. Cancer Ther.

Migliardi et al., 2012, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas., Clin. Cancer Res.

TALC: BEZ235
- Version: 12-May-2016
Alternate Names:

BEZ235 Primary Drug Name

BEZ235 Drug Synonym

Drug Info:

Publications:
TTD: BEZ235
- Version: 2020.06.01
Alternate Names:

D0VG0D TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1879463
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: DACTOLISIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: NVP-BEZ235
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: NVP-BEZ235
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1879463
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

combination therapy	BEZ235 + Ruxolitinib
Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive

Mechanism of Interaction	PI3-kinase class I inhibitor
Direct Interaction	yes
Reported Cancer Type	Melanoma

combination therapy	BEZ235 + Binimetinib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Selumetinib + BEZ235
Indication/Tumor Type	endometrial cancer
Response Type	sensitive

Indication/Tumor Type	thyroid cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	BEZ235 + Vemurafenib
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	Sorafenib + BEZ235
Indication/Tumor Type	urinary bladder cancer
Response Type	sensitive

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Pimasertib + BEZ235
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

Response Type	resistant
Response Type	decreased response
Response Type	sensitive

Dactolisib	PubChem Drug Name
11977753	PubChem Drug ID
BEZ235	Drug Trade Name

DACTOLISIB Drug Record

DACTOLISIB chembl:CHEMBL1879463 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BEZ235 + Ruxolitinib Indication/Tumor Type Advanced Solid Tumor Response Type sensitive

PMIDs: 24251790

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes Reported Cancer Type Melanoma

PMIDs: 23619167 19029981 26270481 26232337 28446642 24927217 26137449 21966435 26013318 26272063 23629727 27974663 22543857 24939055 23475782 26627007 22662154 19010894

Sources: ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: ClearityFoundationBiomarkers MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BEZ235 + Binimetinib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 26206338

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type sensitive Approval Status Preclinical

PMIDs: 22392911 19029981 23629727 25673820 24939055 23475782 22662154 26272063 26232337 26206338

Sources: JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Selumetinib + BEZ235 Indication/Tumor Type endometrial cancer Response Type sensitive

PMIDs: 28446642 27974663 26206338 22662154 26232337

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
24251790

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

Reported Cancer Type Melanoma

PMIDs:
23619167 19029981 26270481 26232337 28446642 24927217 26137449 21966435 26013318 26272063 23629727 27974663 22543857 24939055 23475782 26627007 22662154 19010894

Sources:
ClearityFoundationBiomarkers MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Binimetinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
26206338

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22392911 19029981 23629727 25673820 24939055 23475782 22662154 26272063 26232337 26206338

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + BEZ235

Indication/Tumor Type endometrial cancer

Response Type sensitive

PMIDs:
28446642 27974663 26206338 22662154 26232337

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
21831957

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

PMIDs:
23410005

Sources:
DTC MyCancerGenome ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial TTD

Interaction Types & Directionality:

n/a